Skip Navigation


QJM Advance Access originally published online on October 1, 2008
QJM 2008 101(12):991; doi:10.1093/qjmed/hcn132
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/12/991    most recent
hcn132v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Taylor, R.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, R.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Use of fresh frozen plasma to enhance the therapeutic action of rituximab

Sir,

I was very pleased to read the recent report by Dr Klepfish and his colleagues (published online July 23, 2008) in which they demonstrated that fresh frozen plasma could be used to dramatically enhance the therapeutic action of rituximab in the treatment of chronic lymphocytic leukemia (CLL). In this article, they noted that in 2004 our laboratory reported, in the Journal of Immunology1 that in CLL ‘complement may be rapidly depleted as a consequence of RTX therapy.’ However, the present report by Dr Klepfish and colleagues did not acknowledge that in our 2004 paper we also made the following statement, ‘Therefore, we suggest that if complement is required to promote killing of RTX-opsonized cells, then use of C2, or compatible fresh frozen plasma as a complement source, may enhance the action of RTX in patients with reduced or depleted complement levels.’ We are very pleased to see that the treatment paradigm we first proposed more than 4 years ago appears to be validated by the work of Dr Klepfish and colleagues.

R.P. Taylor

Department of Biochemistry and Molecular Genetics,
University of Virginia School of Medicine,
Charlottesville, Virginia 22908, USA

Reference

1. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. (2004) 172:3280–8.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/12/991    most recent
hcn132v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Taylor, R.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, R.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?